ENTRY       D10586            Mixture   Drug
NAME        Dapagliflozin and metformin;
            Xigduo xr (TN)
PRODUCT     XIGDUO (AstraZeneca Pharmaceuticals LP)
COMPONENT   (Dapagliflozin [DR:D08897] | Dapagliflozin propylene glycolate hydrate [DR:D09763]), (Metformin hydrochloride [DR:D00944] | Metformin [DR:D04966])
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG03034  Combination of metformin and SGLT2 inhibitor
REMARK      ATC code: A10BD15
            Product: D10586<US>
EFFICACY    Antidiabetic
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BD Combinations of oral blood glucose lowering drugs
                 A10BD15 Metformin and dapagliflozin
                  D10586  Dapagliflozin and metformin &lt;US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Combinations
               Dapagliflozin/ Metformin Hydrochloride
                D10586  Dapagliflozin and metformin
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG03034  Combination of metformin and SGLT2 inhibitor
                D10586  Dapagliflozin and metformin
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D10586  Dapagliflozin and metformin
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10586
DBLINKS     PubChem: 254741548
///
